GCP
KRYS icon

GSA Capital Partners’s Krystal Biotech KRYS Stock Holding History

GSA Capital Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,464
Closed -$543K – 1882
2024
Q4 		$543K Buy
+3,464
New +$614K 0.04% 826

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

GSA Capital Partners's KRYS Position: Q1 2025 in Review

GSA Capital Partners sold out of Krystal Biotech (KRYS) in Q1 2025, closing a stake of 3,464 shares — an estimated $543K sold.

GSA Capital Partners first reported a position in KRYS in Q4 2024 and held it in 1 quarter. The position peaked at $543K in Q4 2024. 299 funds tracked by Wall St. Rank hold KRYS as of Q1 2025.

  • GSA Capital Partners reported no remaining Krystal Biotech position as of Q1 2025 after selling out during the quarter.
  • GSA Capital Partners sold 3,464 Krystal Biotech shares in Q1 2025, an estimated $543K.
  • GSA Capital Partners first reported a position in Krystal Biotech in Q4 2024 and held it in 1 quarter.
  • GSA Capital Partners's Krystal Biotech position peaked at $543K in Q4 2024.
  • 299 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2025.

Based on GSA Capital Partners's 13F filing for Q1 2025, filed 8 May 2025.